コンテンツへスキップ
Merck
  • High prevalence of fluoroquinolone-resistant group B streptococci among clinical isolates in China and predominance of sequence type 19 with serotype III.

High prevalence of fluoroquinolone-resistant group B streptococci among clinical isolates in China and predominance of sequence type 19 with serotype III.

Antimicrobial agents and chemotherapy (2013-01-09)
Hui Wang, Chunjiang Zhao, Wenqiang He, Feifei Zhang, Liyan Zhang, Bin Cao, Ziyong Sun, Yingchun Xu, Qing Yang, Yaning Mei, Bijie Hu, Yunzhuo Chu, Kang Liao, Yunsong Yu, Zhidong Hu, Yuxing Ni
要旨

A total of 146 group B streptococcus isolates from 8 cities across China belonged to four serotypes. Serotype Ia was more common in children. A high prevalence of resistance was observed for levofloxacin (37.7%), erythromycin (71.2%), clindamycin, (53.4%), and tetracycline (81.5%). The levofloxacin and clindamycin resistances among the 4 serotypes differed significantly. Eighty percent of fluoroquinolone-resistant isolates belonged to the sequence type 19 (ST19)/serotype III clone, with GyrA-ParC-ParE triple substitutions. This clone carried the erm(B), mef(E), and tet(M) genes.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
クリンダマイシン 塩酸塩, lincosamide antibiotic
Supelco
Clindamycin hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
クリンダマイシン 塩酸塩, European Pharmacopoeia (EP) Reference Standard